Cargando…
Effect of increase in duration of aprepitant consumption from 3 to 6 days on the prevention of nausea and vomiting in women receiving combination of anthracycline/cyclophosphamide chemotherapy: A randomized, crossover, clinical trial
BACKGROUND: Aprepitant is one of the effective antiemetic drugs that usually used for a period of 3 days for prevention of anthracycline/cyclophosphamide (AC) induced nausea and vomiting. However, many patients still experience nausea and vomiting on days 3–5. The aim of this study was to evaluate t...
Autores principales: | Ahvazi, Negah Chaabi, Hemati, Simin, Mohamadianpanah, Mohamad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673705/ https://www.ncbi.nlm.nih.gov/pubmed/26682204 http://dx.doi.org/10.4103/2277-9175.168605 |
Ejemplares similares
-
Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: A retrospective study
por: Kawazoe, Hitoshi, et al.
Publicado: (2018) -
The efficacy of combination of ondansetron and aprepitant on preventing the radiotherapy-induced nausea and vomiting
por: Emami, Hamid, et al.
Publicado: (2015) -
Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy
por: Kosaka, Yoshimasa, et al.
Publicado: (2015) -
Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting
por: Chrisp, Paul
Publicado: (2007) -
The efficacy of aprepitant for the prevention of postoperative nausea and vomiting: A meta-analysis
por: Liu, Yingchao, et al.
Publicado: (2023)